Frequently Asked Questions

Peptides are short chains of amino acids, typically containing between 2 and 50 amino acids linked by peptide bonds. They function as signaling molecules in the body, triggering specific biological responses when they bind to cell receptors. While proteins are also made of amino acids, peptides are smaller and often easier for the body to absorb.

Peptides and steroids are completely different compounds. Peptides are chains of amino acids that work with your body's natural signaling pathways, while anabolic steroids are synthetic hormones derived from testosterone. Peptides generally have fewer side effects and work by enhancing natural bodily processes rather than introducing external hormones.

The legal status of peptides varies by country and specific compound. Many peptides are available for research purposes, while some are approved for medical use. In the United States, certain peptides like semaglutide and tirzepatide are FDA-approved medications. Always check your local regulations and consult with a healthcare provider.

Some peptides require a prescription from a licensed healthcare provider, while others are available as research compounds. FDA-approved peptides like semaglutide require a prescription. We recommend consulting with a knowledgeable healthcare provider before starting any peptide protocol.

PeptIQ references primary scientific sources and registry data where available, including PubMed-indexed literature and trial registries. Our educational pages link out to source materials so you can validate claims directly.

Yes. Peptide evidence often spans in-vitro, animal, and human studies. PeptIQ surfaces study context and strength so users can understand what is mechanistic, what is preclinical, and what is supported by clinical data.

Most therapeutic peptides are administered via subcutaneous injection into the fatty tissue beneath the skin. Common injection sites include the abdomen, thigh, and deltoid area. Some peptides are available as nasal sprays or oral formulations, though these are less common.

Reconstitution is the process of mixing bacteriostatic water with lyophilized (freeze-dried) peptide powder to create an injectable solution. You'll need to calculate the proper amount of water based on your desired concentration and inject it gently into the vial, allowing it to dissolve without shaking.

Reconstitution means dissolving lyophilized (freeze-dried) peptide powder into a sterile liquid so it can be measured and injected. For a first-timer the safe sequence is: wash your hands, swab the vial stopper with a fresh alcohol pad and let it air-dry, slowly add your measured bacteriostatic water down the inside wall of the vial, then swirl gently until clear instead of shaking. Draw each dose with a single-use insulin syringe. Beginners working toward goals like weight management most often track the vial amount, the diluent volume they added, the resulting concentration, and each dose in a log so the math stays consistent across a vial. This is general education, not a directive to use any compound.

Concentration is the peptide amount divided by the diluent volume. Convert milligrams to micrograms first (1 mg equals 1000 mcg). Example: a 5 mg vial holds 5000 mcg; add 2 mL of bacteriostatic water and the concentration becomes 2500 mcg/mL. To find how much to draw, divide your desired dose by the concentration, so a 250 mcg dose is 250 / 2500 equals 0.1 mL. On a 100-unit (1 mL) insulin syringe that 0.1 mL equals 10 units. The core formulas are volume (mL) equals desired dose (mcg) divided by concentration (mcg/mL), and syringe units equals volume (mL) times 100. PeptIQ reconstitution and dosage calculators run this same math so you avoid mixing mg and mcg.

Aseptic technique is what keeps a multi-dose vial from becoming contaminated. Core practices public-health bodies emphasize include hand hygiene before handling, disinfecting the vial stopper with alcohol and letting it dry before every puncture, using a new sterile needle and syringe for each draw, and never touching or reusing needles. The U.S. CDC injection safety guidance and the WHO best practices for injections both center on single-use devices and never reusing needles or syringes to prevent bloodborne infection, and USP General Chapter 797 describes the aseptic standards for sterile compounding. Add diluent slowly, swirl instead of shaking to protect the peptide, refrigerate the reconstituted vial away from light, and discard any vial that is cloudy, discolored, or has visible particles.

Because a manufacturer insert or a licensed clinician's instructions are specific to the exact product formulation, concentration, approved diluent, and to your individual health situation, while community norms are generalized and may not fit your vial or goals. Prescription and FDA-regulated products ship with labeling and prescribing information that reflect data reviewed by regulators; many research peptides are labeled research use only and have not been evaluated for human use at all. When community guidance conflicts with the printed label, the pharmacy insert, or a clinician's direction, follow the label and your clinician first. Use community norms and calculators to understand the process and prepare questions, not to override product-specific or medical instructions.

Reconstitution volume is arithmetic, not a fixed rule: the concentration you end up with equals the milligrams of peptide in the vial divided by the milliliters of bacteriostatic (BAC) water you add. For a 15 mg retatrutide vial, adding 1.5 mL of BAC water gives 10 mg/mL, adding 2 mL gives 7.5 mg/mL, and adding 3 mL gives 5 mg/mL — the total drug in the vial never changes, only the concentration. On a U-100 insulin syringe (100 units = 1 mL), a 10 mg/mL solution means each 10-unit (0.1 mL) mark holds 1 mg, so a 2 mg dose is 20 units and a 5 mg dose is 50 units. Community trackers commonly choose a water volume that makes their planned titration doses land on round syringe marks and that keeps the fill at or below their syringe's capacity; retatrutide was studied at 1–12 mg once weekly in its Phase 2 obesity trial (Jastreboff AM et al., NEJM 2023, PMID 37354027). There is no single 'correct' amount of water. Follow any pharmacy label or product insert first, and log the exact volume you used so your dose math stays consistent.

Two formulas cover almost every reconstitution question. First, concentration (mg/mL) = peptide mass in the vial (mg) ÷ bacteriostatic water added (mL). Second, on a U-100 insulin syringe the units to draw = (your dose in mg ÷ concentration in mg/mL) × 100. Example: a 10 mg vial reconstituted with 2 mL of BAC water is 5 mg/mL, so a 0.5 mg dose is (0.5 ÷ 5) × 100 = 10 units. Pick a water volume so your usual dose lands on an easy-to-read mark and the total fill stays within your syringe's capacity — changing the water volume changes the concentration and the units you draw, never the total milligrams in the vial. PeptIQ's reconstitution and unit-conversion tools run this math for you, and you should defer to a pharmacy label or product insert whenever one is provided.

For subcutaneous peptide injections, insulin syringes are typically used. The most common choices are 29-31 gauge needles with 0.3mL, 0.5mL, or 1mL capacity. Smaller gauges (higher numbers) mean thinner needles, which are generally more comfortable for subcutaneous injections.

You should rotate injection sites with each administration to prevent tissue damage, scarring, and absorption issues. Use a systematic approach, such as dividing the abdomen into quadrants or alternating between different body areas. The PeptIQ app includes an injection site tracker to help you stay organized.

Some protocols combine compatible peptides in one draw, while others must be dosed separately for stability or safety reasons. Same-syringe mixing is only appropriate when both compounds share a compatible diluent, pH range, and post-mix stability window, and when no chemical interaction is expected between the two sequences. When compatibility is not documented, the safer default is to reconstitute and inject each peptide separately. Always confirm compatibility with a licensed provider and follow sterile preparation standards before combining compounds.

Same-syringe compatibility depends on matching the diluent, pH range, concentration, and post-mix stability of both compounds, plus the absence of chemical interactions between the two sequences. Without a specific compatibility source or pharmacy guidance, treat two peptides as incompatible and inject them separately. Higher-risk combinations include fragile growth hormone secretagogues (Tesamorelin, Ipamorelin, CJC-1295), copper-containing peptides such as GHK-Cu (copper can catalyze oxidation of other peptides), GLP-1 or GIP agonists, and anything that is not a peptide such as NAD+. Separate injections remove the guesswork, preserve dosing accuracy, and avoid degrading either compound.

There is no published physicochemical compatibility data confirming that Epithalon (Ala-Glu-Asp-Gly) can be safely combined in the same syringe with other peptides, so the conservative default is to reconstitute and inject it on its own. Epithalon is typically reconstituted with bacteriostatic water and dosed on short 10 to 20 day cycles, which makes a dedicated draw easy to plan. Combining peptides in one syringe only saves an injection when both compounds share a compatible diluent, pH, and stability window, and those factors are not established for Epithalon co-formulation. Keep growth hormone secretagogues, copper peptides like GHK-Cu, GLP-1 or GIP agonists, and non-peptides such as NAD+ in their own syringes, and confirm any combination with a licensed provider before mixing.

PeptIQ includes reconstitution, dosage, and unit conversion tools, plus protocol tracking and logging history. These tools reduce unit confusion and support consistent administration workflows.

Unreconstituted peptides should be stored in a cool, dry place away from light. Refrigeration (36-46°F / 2-8°C) is recommended for long-term storage. Once reconstituted, peptides must be refrigerated and typically remain stable for 2-4 weeks, depending on the specific compound.

Unreconstituted peptides can generally be frozen for extended storage. However, once reconstituted, freezing is not recommended as it can damage the peptide structure. Always check specific storage guidelines for each peptide.

Most reconstituted peptides remain stable for 2-4 weeks when properly refrigerated. Some peptides may have shorter or longer stability. Using bacteriostatic water (which contains a preservative) extends stability compared to sterile water.

Most multi-dose community workflows use BAC water because preservative support is practical for repeated vial access. Sterile water is commonly used for shorter handling windows or when product-specific guidance requires it. If your pharmacy label or insert gives explicit instructions, follow those first.

Yes. Diluent choice affects practical use windows, storage strategy, and how quickly users plan to finish a vial. Keep your concentration math and timeline notes together so protocol changes do not create dosing confusion.

Traveling with peptides requires careful planning. Keep them in a cooler or insulated bag with ice packs, carry documentation from your healthcare provider if prescribed, and be aware of regulations in your destination. Never store peptides in checked luggage where temperature cannot be controlled.

Cloudiness, unexpected color change, visible particles, unusual odor, and damaged seals can indicate stability or contamination issues. If a vial appears compromised, do not use it and consult your supplier or provider.

Yes. PeptIQ includes vial and inventory tracking with reminders so users can monitor active vials, usage pace, and restock windows in one place.

When sourced from reputable suppliers and used appropriately, many peptides have good safety profiles. However, like any bioactive compound, peptides can have side effects and interactions. Always consult with a healthcare provider before starting any peptide protocol and purchase from tested, quality-controlled sources.

Common side effects vary by peptide but may include injection site reactions, headaches, nausea, flushing, and fatigue. Growth hormone secretagogues may cause water retention or increased hunger. Most side effects are mild and temporary. Severe or persistent side effects should be reported to a healthcare provider.

Yes, peptide stacking (using multiple peptides together) is common and can provide synergistic benefits. However, it requires careful planning regarding timing, compatibility, and dosing. Some peptides complement each other well, while others should not be combined.

Cycling protocols (taking breaks from use) depend on the specific peptide. Some peptides, particularly growth hormone secretagogues, may benefit from cycling to prevent receptor desensitization. Others may be used continuously. Check specific guidelines for each peptide.

Peptides can overlap with pathways affected by common drugs, supplements, and underlying conditions, so review the full picture with a prescribing clinician before starting. Medications worth flagging include NSAIDs and COX inhibitors, corticosteroids, anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin), insulin and other antidiabetic drugs, thyroid medication, immunosuppressants, and anything with a narrow therapeutic window. Supplements to disclose include blood-thinning agents (high-dose fish oil, vitamin E, ginkgo, garlic), and stimulant or hormone-modulating products. Health conditions that warrant extra caution include diabetes or impaired glucose control, thyroid disease, cardiovascular disease, active or prior malignancy (because several recovery peptides are pro-angiogenic), pregnancy or breastfeeding, and significant liver or kidney impairment. Bring a complete list of everything you take so interactions can be assessed against your specific history.

Possibly, and the direction of the interaction differs by drug class. BPC-157 has been studied specifically against NSAID toxicity — in a diclofenac model it counteracted gastrointestinal, liver, and encephalopathy lesions — but that does not make combining NSAIDs with peptides validated or safe in humans, and NSAIDs can independently blunt tendon and bone healing through COX-2 inhibition. Corticosteroids suppress collagen synthesis and TGF-β signaling, which mechanistically opposes the healing pathways recovery peptides upregulate, so combining them can work against your goal. Anticoagulants and antiplatelet drugs deserve particular attention because several recovery peptides influence angiogenesis and nitric-oxide signaling; none of these combinations have been tested in controlled human trials, so timing, spacing, and whether to combine at all should be decided with a clinician. Use the interaction data as evidence and community norms to inform that conversation, not as a protocol.

Certain conditions change the risk calculus enough that they should be reviewed with a clinician first. Growth-hormone secretagogues (CJC-1295, ipamorelin, sermorelin, MK-677) can raise blood glucose and IGF-1, so diabetes, insulin resistance, or a personal or family history of cancer are important to disclose. A history of or active malignancy is relevant across pro-angiogenic recovery peptides such as BPC-157 and TB-500, since promoting new blood-vessel growth is theoretically undesirable in that setting. Thyroid disease, cardiovascular disease, uncontrolled hypertension, pregnancy or breastfeeding, and significant liver or kidney impairment also change how a peptide is metabolized or tolerated. These are education and evidence points to discuss with your provider — not reasons to self-adjust a prescribed treatment.

Strong preclinical data can indicate promising mechanisms, but it does not guarantee equivalent human outcomes. Good evidence interpretation includes model type, sample size, endpoint quality, and whether findings were replicated in human cohorts.

Yes. PeptIQ includes a claim-auditing workflow that analyzes social claims against scientific evidence context and flags when language overstates available data.

Use a cost-per-mg workflow, not just sticker price. Two vials can look similar in price but differ significantly in active amount, concentration flexibility, and dose efficiency. A fair comparison includes cost per mg, cost per target dose, and estimated monthly spend at your actual schedule.

Start with your target dose and frequency, then calculate dose count per month and multiply by cost per dose. If your schedule varies week-to-week, model both baseline and high-usage scenarios to avoid underestimating budget needs.

Map vial duration against your dosing cadence and expected stability window after reconstitution. A larger vial is not always better if the protocol pace is slow and stability expires before the vial is fully used.

Yes. PeptIQ includes reconstitution, dosage, and unit-conversion workflows so users can move from vial concentration assumptions to practical syringe-ready outputs in one process.

The most common issues are mixing mg and mcg units, forgetting to log BAC volume, and reusing old concentration assumptions after protocol changes. Keeping one canonical calculator workflow and recording assumptions with each vial reduces these errors.

Half-life is the time it takes for an estimated amount of compound to drop by 50% in the body. It helps users plan timing expectations and spacing decisions, but it does not by itself define complete clinical effect or individualized response.

A common rule of thumb is that around 5 half-lives approaches about 95% clearance, and around 7 half-lives approaches about 99% clearance. This is a simplification, but it provides a useful planning baseline for schedule discussions.

No. Even peptides with related use cases can differ meaningfully in half-life by sequence, formulation, route, and study context. Always verify peptide-specific data before applying schedule assumptions from another compound.

Half-life references are more useful when paired with real schedule logs, because practical execution often differs from ideal timing. Combining both helps users identify whether protocol drift may be affecting consistency.

No. Half-life and clearance calculators are educational planning tools. They are useful for understanding timing concepts but do not replace individualized clinical guidance or safety review.

Start by separating mechanism claims, preclinical claims, and human-outcome claims. Then cross-check each claim against primary sources like FDA materials, ClinicalTrials.gov records, and PubMed studies before treating it as established.

Key quality markers include sample size, endpoint relevance, study design, replication, and whether results come from animals, in-vitro models, or human trials. Strong interpretation depends on context, not headline language alone.

PeptIQ is designed to surface evidence context instead of presenting every claim as settled fact. Users can review references, understand confidence differences, and make better-informed questions for licensed providers.

FDA-approved peptides have specific indications and reviewed safety/efficacy data for those uses. Research-only peptides do not carry the same approval status and should not be interpreted as equivalent to approved therapies.

Answer-engine optimized FAQ pages make core concepts easier to retrieve in voice and AI-assisted search. Better structured answers also help users compare options faster and reduce confusion from fragmented sources.

PeptIQ is a comprehensive peptide education and tracking app. It includes dose logging, injection site map, inventory management, calculators, vial duration and cost tools, interaction checker, peptide comparison, a broad peptide library, educational articles, glossary terms, and FAQs. Premium adds AI features, unlimited peptides and protocols, full history, smart reminders, cloud sync, and export.

PeptIQ Premium is a paid subscription. There is no perpetual free tier for the full app experience. Weekly, monthly, and annual billing are available via the App Store or web checkout. Some website calculator tools may exist separately and are not a substitute for Premium.

Yes, PeptIQ is designed with privacy as a priority. All your data is stored locally on your device. We don't require account creation for basic functionality and never sell or share your personal health information.

PeptIQ is available on iOS (App Store) and Android (Google Play). Download the app to start tracking your peptide protocols today.

PeptIQ maintains broad coverage across peptide profiles, linked references, FAQs, glossary definitions, and educational guides, with continuous updates to improve citation depth and answer quality.

PeptIQ's AI tooling is designed to retrieve internal peptide knowledge first (profiles, references, FAQ, glossary context) before generating explanations, helping responses stay grounded in your curated dataset.

In STEP trials, durable weight and cardiometabolic benefits assume ongoing once-weekly semaglutide treatment. STEP 1 showed large mean weight loss over ~68 weeks; the STEP 1 off-treatment extension found participants regained about two-thirds of prior weight loss within a year after stopping therapy. STEP 5 found continued treatment through 104 weeks maintained substantial loss versus placebo. GI side effects during titration are a common practical adherence barrier. This is education about published trials — not medical advice.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is studied for stimulating collagen types I and III, elastin, and glycosaminoglycans in fibroblast and wound models. Foundational work by Maquart and colleagues (1988 fibroblast cultures; 1993 rat wound chambers) showed concentration-dependent collagen and connective-tissue accumulation. Copper delivery also supports cuproenzymes involved in collagen cross-linking. Human evidence is strongest in topical/cosmetic contexts; large injectable RCTs remain limited. Research education only — not medical advice.

Half-life is the time for about half of a dose to leave the bloodstream or be broken down. Shorter half-life peptides are often logged more frequently (daily or twice daily); longer half-life compounds may support weekly schedules. For recovery goals, community education often discusses BPC-157 as shorter-acting (more frequent dosing) and TB-500 narratives as longer-acting (less frequent). Always prefer product labels and clinician instructions over community norms. Not medical advice.

Published human data on co-drawing Epithalon (Epitalon/AEDG) with other research peptides is scarce. Community education often treats short water-soluble BAC-water peptides as compatible in principle, but separate syringes remain the conservative default — especially with larger GHRH analogs like Tesamorelin, and always keep NAD+ or non-peptide injectables separate. Inject promptly after drawing; if a mix turns cloudy, discard and separate. Not medical advice.

Reconstitution ratios are community education, not pharmacy labels. A common round math choice for a 15 mg retatrutide research vial is 1.5 mL bacteriostatic water → 10 mg/mL (0.1 mL / 10 units ≈ 1 mg). Alternatives include 3.0 mL → 5 mg/mL or 1.0 mL → 15 mg/mL. Swab vials, inject diluent slowly down the sidewall, swirl gently, and refrigerate. Follow any product-specific insert. Not medical advice.

Discuss with a clinician before starting: NSAIDs/COX inhibitors (may blunt healing), corticosteroids (antagonize repair pathways), anticoagulants/antiplatelets, diabetes or GLP-1/GIP agents when stacking incretins, immunosuppressants, and high-bleeding-risk supplements. Conditions often flagged for review include active cancer or unexplained growths (angiogenesis concerns), uncontrolled diabetes, pregnancy/breastfeeding, severe kidney/liver disease, and upcoming surgery. This is a clinician-review checklist — not advice to start or stop therapy.